Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Zhongnan Xu, Yanli Wang, Guangwen Liu, Jiahui Chen, Wanhua Wang, Yang Cheng, Qing Ren, Yingzi Cui, Wei Yang, Zhengzhi Liu, Xuesong Chen, Jinling Xue, Tianying Chang, Xinyao Qu, Shuang Yu, Yannan Zhou, Kaibo Xu, Zhengjie Su, Qiaohuan Deng, Yicheng Zhao & Haimiao Yang. (2022) A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects. Expert Opinion on Investigational Drugs 31:7, pages 737-746.
Read now
Read now
Giusy Elia, Silvia Martina Ferrari, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Salvatore Ulisse, Salvatore Benvenga, Alessandro Antonelli & Poupak Fallahi. (2022) Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. Expert Opinion on Pharmacotherapy 23:5, pages 599-610.
Read now
Read now
Fabián Pitoia & Fernando Jerkovich. (2016) Selective use of sorafenib in the treatment of thyroid cancer. Drug Design, Development and Therapy 10, pages 1119-1131.
Read now
Read now
Beth A Fordham, Cicely Kerr, Hayley M de Freitas, Andrew J Lloyd, Karissa Johnston, Corey L Pelletier, Gabriel Tremblay, Anna Forsythe, Bryan McIver & Ezra EW Cohen. (2015) Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Preference and Adherence 9, pages 1561-1572.
Read now
Read now
Jolanta Krajewska, Aleksandra Kukulska & Barbara Jarzab. (2015) Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opinion on Drug Safety 14:12, pages 1935-1943.
Read now
Read now
Wendy Sacks & Glenn D Braunstein. (2015) Clinically meaningful end points in the evolving treatment paradigm for radioactive iodine-refractory differentiated thyroid cancer. Expert Review of Endocrinology & Metabolism 10:3, pages 337-344.
Read now
Read now
Jolanta Krajewska & Barbara Jarzab. (2014) Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. Expert Opinion on Orphan Drugs 2:12, pages 1331-1340.
Read now
Read now
Dawn M Elfenbein, Randall P Scheri, Sanziana Roman & Julie A Sosa. (2013) Detection and management of cervical lymph nodes in papillary thyroid cancer. Expert Review of Endocrinology & Metabolism 8:4, pages 365-378.
Read now
Read now
Articles from other publishers (31)
Hao Zhao, Chun-Hao Liu, Yue Cao, Li-Yang Zhang, Ya Zhao, Yue-Wu Liu, Hong-Feng Liu, Yan-Song Lin & Xiao-Yi Li. (2022) Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Crossref
Amit Kumar Choudhary, George Abraham, Vijay Maruti Patil, Nandini Menon, Tanmoy Mandal, Sobin Jacob, Keshav Garg, Anbarasan Sekar, Rup Jyoti Sarma, Laxma Reddy, Dipti Nakti, Neha Mittal, Munita Bal, Swapnil Rane, Nilendu Purandare, Abhishek Mahajan, Nilesh Sable, Suman Kumar, Vanita Noronha & Kumar Prabhash. (2021) Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian Journal of Surgical Oncology 13:1, pages 81-86.
Crossref
Crossref
Wei Chen, Yu kun Luo, Ying Zhang, Qing Song & Jie Tang. (2021) Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma. BMC Cancer 21:1.
Crossref
Crossref
Li Zhang, Shichen Xu, Xian Cheng, Jing Wu, Xiaowen Wang, Liying Wu, Huixin Yu & Jiandong Bao. (2021)
Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
via
suppression of the PI3K-AKT signaling pathway
. Food & Function 12:18, pages 8260-8273.
Crossref
Crossref
Elisa Lodi Rizzini, Andrea Repaci, Elena Tabacchi, Lucia Zanoni, Valentina Vicennati, Ottavio Cavicchi, Uberto Pagotto, Alessio Giuseppe Morganti, Stefano Fanti & Fabio Monari. (2021) Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). Diagnostics 11:8, pages 1430.
Crossref
Crossref
Luis Felipe Fierro-Maya, Gloria Garavito González, Leonardo Javier Rojas Melo, Andrés Arturo Cuéllar Cuéllar, Alexander Carreño & Claudia Córdoba. (2021) Safety and efficacy of sorafenib in patients with advanced thyroid carcinoma: a phase II study (NCT02084732). Archives of Endocrinology and Metabolism.
Crossref
Crossref
Luc H.J. Sondorp, Vivian M.L. Ogundipe, Andries H. Groen, Wendy Kelder, Annelies Kemper, Thera P. Links, Robert P. Coppes & Schelto Kruijff. (2020) Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening. Cancers 12:11, pages 3212.
Crossref
Crossref
M. E. Cabanillas & S. Takahashi. (2020) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Head and Neck Tumors (HNT) 9:4, pages 49-61.
Crossref
Crossref
T. M. Geliashvili, A. V. Vazhenin, T. P. Berezovskaya, N. G. Afanasyeva, E. V. Vasilyeva, P. I. Garbuzov & V. V. Krylov. (2020) <sup>18</sup>F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer. Head and Neck Tumors (HNT) 9:4, pages 10-16.
Crossref
Crossref
Anna Zelinskaya, Andrey Kvachenyuk, Galina Kulinichenko & Victoria Moroz. (2020) CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS. EUREKA: Life Sciences 1, pages 3-10.
Crossref
Crossref
Hye-Seon OhDong Yeob ShinMijin KimSo Young ParkTae Hyuk KimBo Hyun KimEui Young KimWon Bae KimJae Hoon ChungYoung Kee ShongDong Jun LimWon Gu Kim. (2019) Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. Thyroid 29:12, pages 1804-1810.
Crossref
Crossref
Eun Kyung LeeSeok-Mo KimBo Hyun KimMin Joo KimDong-Jun LimMin-Hee KimDong Yeob ShinHo-Cheol KangByeong-Cheol AhnSun Wook KimHwa Young AhnYoung Joo Park. (2019) Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study. Thyroid 29:12, pages 1811-1819.
Crossref
Crossref
Seo Young Kang, Ji-In Bang, Keon Wook Kang, Ho-young Lee & June-Key Chung. (2019) FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma. PLOS ONE 14:6, pages e0218416.
Crossref
Crossref
Anna Zelinskaya. (2019) CHARACTERISTICS OF SUBCLONAL STRUCTURE IN THYROCYTE POPULATION IN RADIOIODINE-REFRACTORY METASTASES OF PAPILLARY THYROID CANCER. EUREKA: Life Sciences 3, pages 3-9.
Crossref
Crossref
Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Naoki Fukuda, Tatsuya Sasaki, Takuya Suzuki, Hiroki Ikezawa, Corina E Dutcus & Makoto Tahara. (2019) A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncology 15:7, pages 717-726.
Crossref
Crossref
Maria E. Cabanillas & Shunji Takahashi. (2019) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Seminars in Oncology 46:1, pages 57-64.
Crossref
Crossref
A. G. GianoukakisC. E. DutcusN. BattyM. GuoM. Baig. (2018) Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation). Head and neck tumors (HNT) 8:3, pages 53-60.
Crossref
Crossref
Andrey P. Polyakov, Alexander V. Mordovskiy, Petr A. Nikiforovich, Mikhail V. Ratushnyy, Irina V. Rebrikova, Anna V. Boyko, Larisa V. Bolotina & Artem R. Gevorcov. (2018) CLINICAL CASES OF THE EFFICACY OF THERAPY MULTIKINASE INHIBITORS OF METASTATIC RADIOID-REFRACTORY DIFFERENTIATED THYROID CANCER. Endocrine Surgery 12:2, pages 81-88.
Crossref
Crossref
M. S. Brose, F. P. Worden, K. L. Newbold, M. Guo & A. Hurria. (2018) Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial. Head and neck tumors (HNT) 8:2, pages 39-52.
Crossref
Crossref
Andrew G Gianoukakis, Corina E Dutcus, Nicolas Batty, Matthew Guo & Mahadi Baig. (2018) Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocrine-Related Cancer 25:6, pages 699-704.
Crossref
Crossref
Naomi KiyotaBruce RobinsonManisha ShahAna O. HoffMatthew H. TaylorDi LiCorina E. DutcusEun Kyung LeeSung-Bae KimMakoto Tahara. (2017) Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Thyroid 27:9, pages 1135-1141.
Crossref
Crossref
Marcia S. BroseFrancis P. WordenKate L. NewboldMatthew GuoArti Hurria. (2017) Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. Journal of Clinical Oncology 35:23, pages 2692-2699.
Crossref
Crossref
Nadia Sawicka-Gutaj, Joanna Waligórska-Stachura, Mirosław Andrusiewicz, Maciej Biczysko, Jerzy Sowiński, Jerzy Skrobisz & Marek Ruchała. (2015) Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression. Tumor Biology 36:10, pages 7859-7863.
Crossref
Crossref
E. Nilüfer Güler, Murat Fani Bozkurt, Serdar Ozbas & Suayib Yalcin. 2015. Neuroendocrine Tumours. Neuroendocrine Tumours
353
388
.
HEQING YI, BIN LONG, XUEMEI YE, LIJUN ZHANG, XIAODONG LIU & CHUNYAN ZHANG. (2014) Autophagy: A potential target for thyroid cancer therapy (Review). Molecular and Clinical Oncology 2:5, pages 661-665.
Crossref
Crossref
Fabián Pitoia, Fernanda Bueno & Graciela Cross. (2014) Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With 131Iodine-Avid Lung Metastasis From Differentiated Thyroid Cancer. Clinical Nuclear Medicine 39:9, pages 784-790.
Crossref
Crossref
Markus Luster, Theresia Weber & Frederik A. Verburg. (2014) Differentiated thyroid cancer—personalized therapies to prevent overtreatment. Nature Reviews Endocrinology 10:9, pages 563-574.
Crossref
Crossref
Aaron B. Cohen & Marcia S. Brose. (2014) Second-Line Treatment for Advanced Thyroid Cancer: An Indication in Need of Randomized Clinical Trials. The Journal of Clinical Endocrinology & Metabolism 99:6, pages 1995-1997.
Crossref
Crossref
Fabian Pitoia. (2014) Response to sorafenib treatment in advanced metastatic thyroid cancer. Arquivos Brasileiros de Endocrinologia & Metabologia 58:1, pages 37-41.
Crossref
Crossref
Glenda E. Bilder. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
635
643
.
Markus Luster, Theresia Weber & Frederik A. Verburg. (2013) Changes and open issues in the management of differentiated thyroid carcinoma: an overview. Clinical and Translational Imaging 1:3, pages 145-148.
Crossref
Crossref